Immunonutrition in critically ill patients: a systematic review and analysis of the literature
- 1.8k Downloads
The role of immuno-modulating diets (IMDs) in critically ill patients is controversial.
The goal of this meta-analysis was to determine the impact of IMD’s on hospital mortality, nosocomial infections and length of stay (LOS) in critically ill patients. Outcome was stratified according to type of IMD and patient setting.
MEDLINE, Embase, Cochrane Register of Controlled Trials.
RCT’s that compared the outcome of critically ill patients randomized to an IMD or a control diet.
Twenty-four studies (with a total of 3013 patients) were included in the meta-analysis; 12 studies included ICU patients, 5 burn patients and 7 trauma patients. Four of the studies used formulas supplemented with arginine, two with arginine and glutamine, nine with arginine and fish oil (FO), two with arginine, glutamine and FO, six with glutamine alone and three studies used a formula supplemented with FO alone. Overall IMD’s had no effect on mortality or LOS, but reduced the number of infections (OR 0.63; 95% CI 0.47–0.86, P = 0.004, I 2 = 49%). Mortality, infections and LOS were significantly lower only in the ICU patients receiving the FO IMD (OR 0.42, 95% CI 0.26–0.68; OR 0.45, 95% CI 0.25–0.79 and WMD -6.28 days, 95% CI −9.92 to −2.64, respectively).
An IMD supplemented with FO improved the outcome of medical ICU patients (with SIRS/sepsis/ARDS). IMDs supplemented with arginine with/without additional glutamine or FO do not appear to offer an advantage over standard enteral formulas in ICU, trauma and burn patients.
KeywordsImmunonutrition Critical illness ICU Sepsis ARDS Burns Trauma Arginine Omega 3 fatty acids Glutamine Enteral nutrition
Conflict of interest
Dr Marik declares that he has no real or perceived conflict of interest and has no financial interest in any of the products mentioned in this paper. Dr Zaloga declares that he is a paid employee of Baxter Healthcare, Inc. Baxter Healthcare does not manufacture any of the enteral immune modulating diets that are mentioned in the manuscript. Baxter does market a glutamine enteral supplement but did not sponsor any of the trials included in this review.
- 10.Montejo JC, Zarazaga A, Lopez-Martinez J, Urrutia G, Roque M, Blesa AL, Celaya S, Conejero R, Galban C, de Garcia LA, Grau T, Mesejo A, Ortiz-Leyba C, Planas M, Ordonez J, Jimenez FJ (2003) Immunonutrition in the intensive care unit. A systematic review and consensus statement. Clin Nutr 22:221–233PubMedCrossRefGoogle Scholar
- 18.Sato N, Moore FA, Kone BC, Zou L, Smith MA, Childs MA, Moore-Olufemi S, Schultz SG, Kozar RA (2006) Differential induction of PPAR-gamma by luminal glutamine and iNOS by luminal arginine in the rodent postischemic small bowel. Am J Physiol Gastrointest Liver Physiol 290:G616–G623PubMedCrossRefGoogle Scholar
- 24.Bansal V, Syres KM, Makarenkova V, Brannon R, Matta B, Harbrecht BG, Ochoa JB (2005) Interactions between fatty acids and arginine metabolism: implications for the design of immune-enhancing diets. JPEN 29:S75–S80Google Scholar
- 27.Heyland DK, Dhaliwal R, Drover JW, Gramlich L, Dodek P, Canadian critical care clinical practice guidelines committee, Heyland DK, Dhaliwal R, Drover JW, Gramlich L, Dodek P (2003) Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN 27:355–373Google Scholar
- 35.Dent DL, Heyland DK, Levy H, Martindale R, Tayek J, Schloerb P, Kelley MJ (2003) Immunonutrition may increase mortality in critically ill patients with pneumonia: results of a randomized trial. Crit Care Med 30:A17Google Scholar
- 36.Brantley S, Pierce J (2000) Effects of enteral nutrition on trauma patients. Nutr Clin Pract 15:S13Google Scholar
- 39.Bower RH, Cerra FB, Bershadsky B, Licari JJ, Hoyt DB, Jensen GL, van Buuren CT, Rothkopf MM, Daly JM, Adelsberg BR (1995) Early enteral administration of a formula (impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial. Crit Care Med 23:436–449PubMedCrossRefGoogle Scholar
- 40.Rodrigo CM, Garcia PJ (1997) THe effect of the composition of the enteral nutrition on infection in the critical patient (Spanish). Nutr Hosp 12:80–84Google Scholar
- 42.Gadek JE, DeMichele SJ, Karlstad MD, Pacht ER, Donahoe M, Albertson TE, Van Hoozen C, Wennberg AK, Nelson JL, Noursalehi M (1999) Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group. Crit Care Med 27:1409–1420PubMedCrossRefGoogle Scholar
- 45.Caparros T, Lopez J, Grau T (2001) Early enteral nutrition in critically ill patients with a high-protein diet enriched with arginine, fiber, and antioxidants compared with a standard high-protein diet. The effect on nosocomial infections and outcome. JPEN 25:299–308Google Scholar
- 46.Conejero R, Bonet A, Grau T, Esteban A, Mesejo A, Montejo JC, Lopez J, Acosta JA (2002) Effect of a glutamine-enriched enteral diet on intestinal permeability and infectious morbidity at 28 days in critically ill patients with systemic inflammatory response syndrome: a randomized, single-blind, prospective, multicenter study. Nutrition 18:716–721PubMedCrossRefGoogle Scholar
- 51.Gottschlich MM, Jenkins M, Warden GD, Baumer T, Havens P, Snook JT, Alexander JW (1990) Differential effects of three enteral dietary regimens on selected outcome variables in burn patients. JPEN 14:225–236Google Scholar
- 53.Garrel D, Patenaude J, Nedelec B, Samson L, Dorais J, Champoux J, D’Elia M, Bernier J (2003) Decreased mortality and infectious morbidity in adult burn patients given enteral glutamine supplements: a prospective, controlled, randomized clinical trial. Crit Care Med 31:2444–2449PubMedCrossRefGoogle Scholar
- 54.Zhou YP, Jiang ZM, Sun YH, Wang XR, Ma EL, Wilmore D (2003) The effect of supplemental enteral glutamine on plasma levels, gut function, and outcome in severe burns: a randomized, double-blind, controlled clinical trial. JPEN 27:241–245Google Scholar
- 60.Weimann A, Bastian L, Bischoff WE, Grotz M, Hansel M, Lotz J, Trautwein C, Tusch G, Schlitt HJ, Regel G (1998) Influence of arginine, omega–3 fatty acids and nucleotide-supplemented enteral support on systemic inflammatory response syndrome and multiple organ failure in patients after severe trauma. Nutrition 14:165–172PubMedCrossRefGoogle Scholar
- 61.Houdijk AP, Rijnsburger ER, Emmy R, Jansen J, Wesdorp RI, Weiss KK, McCamish MA, Teerlink T, Meuwissen SG, Haarman HJ, Thijs LG, van Leeuwen PA (1998) Randomized trial of glutamine-enriched enteral nutrition on infectious morbidity in patients with mutliple trauma. Lancet 352:772–776PubMedCrossRefGoogle Scholar
- 63.Heyland DK, Novak F (2001) Immunonutrition in the critically ill patient: more harm than good? JPEN 25:S51–S55Google Scholar
- 65.Kalil AC, Sevransky JE, Myers DE, Esposito C, Vandivier RW, Eichacker P, Susla GM, Solomon SB, Csako G, Costello R, Sittler KJ, Banks S, Natanson C, Danner RL (2006) Preclinical trial of l-arginine monotherapy alone or with n-acetylcysteine in septic shock. Crit Care Med 34:2719–2728PubMedCrossRefGoogle Scholar
- 70.Luiking YC, Poeze M, Hendrikx M (2005) Continuous l-arginine infusion does not deteriorate the hemodynamic condition in patients with severe sepsis. Clin Nutr 24:612–613Google Scholar
- 71.Luiking YC, Poeze M, Preiser J (2006) l-arginine infusion in severely septic patients does not enhance protein nitrosylation or haemodynamic instability. e-SPEN 1:14–15Google Scholar
- 72.Mancuso P, Whelan J, DeMichele SJ, Snider CC, Guszcza JA, Claycombe KJ, Smith GT, Gregory TJ, Karlstad MD (1997) Effects of eicosapentaenoic and gamma-linolenic acid on lung permeability and alveolar macrophage eicosanoid synthesis in endotoxic rats. Crit Care Med 25:523–532PubMedCrossRefGoogle Scholar
- 73.Pacht ER, DeMichele S, Nelson JL, Hart J, Wennberg AK, Gadek JE (2003) Enteral nutrition with eicosapentaenoic acid, gamma-linolenic acid, and anti-oxidants reduces alveolar inflammatory mediators and protein influx in patients with acute respiratory distress syndrome. Crit Care Med 31:491–500PubMedCrossRefGoogle Scholar
- 79.O’Dwyer ST, Smith RJ, Hwang TL, Wilmore DW (1989) Maintenance of small bowel mucosa with glutamine-enriched parenteral nutrition. JPEN 13:579–585Google Scholar
- 80.Wischmeyer PE, Lynch J, Liedel J, Wolfson R, Riehm J, Gottlieb L, Kahana M (2001) Glutamine administration reduces Gram-negative bacteremia in severely burned patients: a prospective, randomized, double-blind trial versus isonitrogenous control. Crit Care Med 29:2075–2080PubMedCrossRefGoogle Scholar
- 81.Gianotti L, Alexander JW, Gennari R, Pyles T, Babcock GF (1995) Oral glutamine decreases bacterial translocation and improves survival in experimental gut-origin sepsis. JPEN 19:69–74Google Scholar
- 82.Ameho CK, Adjei AA, Harrison EK, Takeshita K, Morioka T, Arakaki Y, Ito E, Suzuki I, Kulkarni AD, Kawajiri A, Yamamoto S (1997) Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut 41:487–493PubMedCrossRefGoogle Scholar
- 86.Strack van Schijndel RJ, Weijs PJ, Koster C, Bissumbhar A, Melis GC, Girbes AR (2007) A closer look at enterally delivered nutrition in the ICU; what you see is not what they get. e-SPEN 2:1–3Google Scholar
- 88.Beale RJ, Sherry T, Lei K, Campbell-Stephen L, McCook J, Smith J, Venetz W, Alteheld B, Stehle P, Schneider H (2008) Early enteral supplementation with key pharmaconutrients improves Sequential Organ Failure Assessment score in critically ill patients with sepsis: outcome of a randomized, controlled, double-blind trial. Crit Care Med 36:131–144PubMedCrossRefGoogle Scholar